Original Article(s)
Vol. 13 (2025)
Multiple sclerosis diagnosis: free light chain testing as a possible valuable marker in cerebrospinal fluid
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 22 January 2024
Accepted: 15 November 2024
Accepted: 15 November 2024
1424
Views
521
Downloads
Authors
Background: the aim of the study was to assess the importance of free light-chain analysis in the Cerebrospinal Fluid (CSF) for the diagnosis of Multiple Sclerosis (MS) in patients visited at the General Hospital of Alessandria.
Materials and Methods: detecting κFLC and λFLC levels in CSF and serum using Freelite tests on Optilite analyser (The Binding Site) and Isoelectric Focusing (IEF) on Hydrasis 2 analyser (Sebia). Statistical analysis was conducted by GraphPad statistical software and Excel statistical tools. Calculation of p-value by Kruskal-Wallis test and χ2 test. Evaluation of the Free Light Chain (FLC) indices’ performance through the construction of a Receiver Operating Characteristics (ROC) curve.
Results: 132 CSF and serum samples were collected, and 25% of the patients were diagnosed with MS. Through the ROC analysis, the optimal cut-off value was found to be 6,56 for the K index, 10,12 for the λ index, and 0,65 for the IgG index. FLC indices were higher in MS patients than in others.
Conclusions: the study shows that the K index has an equivalent reliability and a higher predictive value, but with lower costs and times than Oligoclonal Bands (OCB). The λ index could have the potential to become a further test used for differential diagnosis of MS, but more in-depth studies via more sensitive techniques are needed to evaluate real performance.
Downloads
Download data is not yet available.
Citations
Sadava D, Heller G, Orians G, et al. Biologia.blu - Il corpo umano. Zanichelli; 2013.
Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002;53:285-302. DOI: https://doi.org/10.1146/annurev.med.53.082901.103909
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765-79. DOI: https://doi.org/10.1001/jama.2020.26858
Agenzia Italiana del Farmaco (AIFA). Aggiornamento della Nota AIFA 65 di cui alla determinazione AIFA n. 354/2018 del 02/03/2018. 2022.
Liu R, Du S, Zhao L, et al. Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target. Front Immunol. 2022;13:996469. DOI: https://doi.org/10.3389/fimmu.2022.996469
Bernardi G, Brunati P, Biagioli T, et al. L’analisi del liquido cefalorachidiano. Biochimica Clinica. 2014;38:238-54.
Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Multiple Sclerosis Journal. 2012;18:552-6. DOI: https://doi.org/10.1177/1352458512443092
Bandiera P, Battaglia MA, Manacorda T, Zaratin P. Barometro della sclerosi multipla e patologie correlate. Associazione Italiana Sclerosi Multipla (AISM). 2022. Available from: https://www.aism.it/presentato-il-barometro-della-sclerosi-multipla-e-patologie-correlate-2023
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-73. DOI: https://doi.org/10.1016/S1474-4422(17)30470-2
Hegen H, Arrambide G, Gnanapavan S, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Mult Scler. 2023;29:182-95. DOI: https://doi.org/10.1177/13524585221134217
Crespi I, Caropreso P, Calcagno L, et al. Il calcolo del kappa index come valida alternativa alla determinazione delle bande oligoclonali nell'iter diagnostico dei pazienti con sclerosi multipla. Biochimica Clinica. 2021. Available from: https://biochimicaclinica.it/wp-content/uploads/2023/03/1681-2020.087_Crespi.pdf
Bernardi G, Cataldo I. La determinazione delle catene leggere libere nel liquido cefalorachidiano: l’esperienza di due laboratori italiani. Soc Ital Biochim Clin E Biol Mol Clin. 2013;37:389-94.
Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand. 2009;119:39-44. DOI: https://doi.org/10.1111/j.1600-0404.2008.01058.x
Fagnart OC, Sindic CJ, Laterre C. Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol. 1988;19:119-32. DOI: https://doi.org/10.1016/0165-5728(88)90041-0
Crespi I, Vecchio D, Serino R, et al. K index is a reliable marker of intrathecal synthesis, and an alternative to IgG index in multiple sclerosis diagnostic work-up. J Clin Med. 2019;8:446. DOI: https://doi.org/10.3390/jcm8040446
Michetti L, Maffina F, Ravasio R, et al. Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases. J Neuroimmunol. 2023;379:578091. DOI: https://doi.org/10.1016/j.jneuroim.2023.578091
Ferraro D, Bedin R, Natali P, et al. Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious/inflammatory CNS disorders. Diagnostics (Basel). 2020;10:856. DOI: https://doi.org/10.3390/diagnostics10100856
Arneth B, Kraus J. The use of kappa free light chains to diagnose multiple sclerosis. Medicina (Kaunas). 2022;58:1512. DOI: https://doi.org/10.3390/medicina58111512
Ferraro D, Trovati A, Bedin R, et al. Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. Eur J Neurol. 2020;27:461-7. DOI: https://doi.org/10.1111/ene.14121
Jakimovski D, Awan S, Eckert SP, et al. Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment. CNS Drugs. 2022;36:45-59. DOI: https://doi.org/10.1007/s40263-021-00887-w
Renoux C, Vukusic S, Mikaeloff Y, et al. Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356:2603-13. DOI: https://doi.org/10.1056/NEJMoa067597
Chitnis T, Aaen G, Belman A, et al. US Network of Paediatric Multiple Sclerosis Centers. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020;143:2733-41. DOI: https://doi.org/10.1093/brain/awaa199
Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261-7. DOI: https://doi.org/10.1177/1352458513484547
Teleanu RI, Niculescu AG, Vladacenco OA, et al. The state of the art of pediatric multiple sclerosis. Int J Mol Sci. 2023;24:8251. DOI: https://doi.org/10.3390/ijms24098251
Hegen H, Berek K, Bsteh G, et al. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study. EBioMedicine. 2023;91:104573. DOI: https://doi.org/10.1016/j.ebiom.2023.104573
Meier S, Willemse EAJ, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80:287-97. DOI: https://doi.org/10.1001/jamaneurol.2022.5250
How to Cite
Multiple sclerosis diagnosis: free light chain testing as a possible valuable marker in cerebrospinal fluid. (2025). Working Paper of Public Health, 13. https://doi.org/10.4081/wpph.2025.9947
Copyright (c) 2025 Cristina Montarolo, Lara Calcagno, Simona Martinotti, Filippo Erli, Antonio Covelli, Fabiana Vercellino, Elia Ranzato, Iacopo Megna
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Iacopo Megna, Serena Penpa, Antonella Cassinari, Christian Leli, Andrea Rocchetti, Annalisa Roveta, Marta Betti, Antonio Maconi, SARS-CoV-2 vs Streptococcus pneumoniae: a comparison of clinical features, laboratory findings, and clinical outcomes in patients hospitalized at Alessandria’s General Hospital , Working Paper of Public Health: Vol. 11 (2023)
- Patrizia Valorio, Simona Giribone, Valentina Manfredi, Monica Franscini, Antonio Pepoli, Rossella Sterpone, Fabiana Vercellino, Maurizio Cremonte, Cognitive, emotional and psycho-educational aspects of epilepsy in childhood: literature review and future perspectives , Working Paper of Public Health: Vol. 10 (2022)
- Sara Cavallar, Elia Ranzato, Thea Bensi, Giuseppina Balza, Lia Mele, Extracorporeal photopheresis (ECP): in vitro assessment of procedure quality , Working Paper of Public Health: Vol. 9 No. 1 (2021)
- Stefania Crivellari, Iacopo Megna, Sara Delfanti, Antonina De Angelis, Oreste Durante, Giulia Merlo, Marco Ghiglione, Federica Grosso, The management of brain metastases in melanoma patients , Working Paper of Public Health: Vol. 10 (2022)
- Ennio Nano, Stefania Erra, Simona Martinotti, Elia Ranzato, Pleural mesothelioma: research of mechanisms involved in carcinogenesis. The role of CD10 , Working Paper of Public Health: Vol. 9 No. 1 (2021)
